Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupret M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, Archambaud B, Belhechmi S, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, Le Teuff G, Derosa L, Marabelle A, Van Dorp J, Van Dijk N, Van Der Heijden MS, Besse B, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Loriot Y. Goubet AG, et al. Among authors: van dorp j, van der heijden ms, van dijk n. Cancer Discov. 2022 Oct 5;12(10):2280-2307. doi: 10.1158/2159-8290.CD-22-0201. Cancer Discov. 2022. PMID: 35929803
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS. Gómez de Liaño Lista A, et al. Among authors: van der heijden ms, van dijk n. Eur Urol. 2020 Feb;77(2):269-276. doi: 10.1016/j.eururo.2019.10.004. Epub 2019 Nov 5. Eur Urol. 2020. PMID: 31699525
Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.
van Dijk N, Gómez de Liaño Lista A, Szabados B, Powles T, van der Heijden MS. van Dijk N, et al. Among authors: van der heijden ms. Eur Urol. 2021 Jan;79(1):e20-e21. doi: 10.1016/j.eururo.2020.10.018. Epub 2020 Nov 3. Eur Urol. 2021. PMID: 33153815 No abstract available.
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N, Gil-Jimenez A, Silina K, van Montfoort ML, Einerhand S, Jonkman L, Voskuilen CS, Peters D, Sanders J, Lubeck Y, Broeks A, Hooijberg E, Vis DJ, van den Broek M, Wessels LFA, van Rhijn BWG, van der Heijden MS. van Dijk N, et al. Among authors: van montfoort ml, van den broek m, van rhijn bwg, van der heijden ms. Front Immunol. 2021 Dec 20;12:793964. doi: 10.3389/fimmu.2021.793964. eCollection 2021. Front Immunol. 2021. PMID: 34987518 Free PMC article. Clinical Trial.
A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.
van Dorp J, van Montfoort ML, van Dijk N, Hofland I, de Feijter JM, Bergman AM, Hendricksen K, van der Poel HG, van Rhijn BWG, van der Heijden MS. van Dorp J, et al. Among authors: van montfoort ml, van rhijn bwg, van der heijden ms, van der poel hg, van dijk n. Clin Genitourin Cancer. 2022 Apr;20(2):e173-e179. doi: 10.1016/j.clgc.2021.12.004. Epub 2021 Dec 10. Clin Genitourin Cancer. 2022. PMID: 35016887 No abstract available.
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Einerhand SMH, van Dijk N, van Dorp J, de Feijter JM, van Montfoort ML, van de Kamp MW, Schaake EE, Boellaard TN, Hendricksen K, van der Heijden MS, van Rhijn BWG. Einerhand SMH, et al. Among authors: van montfoort ml, van rhijn bwg, van dorp j, van de kamp mw, van der heijden ms, van dijk n. Int J Cancer. 2022 Dec 1;151(11):2004-2011. doi: 10.1002/ijc.34125. Epub 2022 Jun 10. Int J Cancer. 2022. PMID: 35603905 Free article. Clinical Trial.
Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer".
Einerhand SMH, van Dijk N, van der Heijden MS, van Rhijn BWG. Einerhand SMH, et al. Among authors: van rhijn bwg, van der heijden ms, van dijk n. Int J Cancer. 2022 Nov 15;151(10):1849-1850. doi: 10.1002/ijc.34207. Epub 2022 Aug 10. Int J Cancer. 2022. PMID: 35815942 Free article. No abstract available.
210 results